Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
HESTER BIOSCIENCES TEVA PHARMA |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
HESTER BIOSCIENCES Mar-23 |
TEVA PHARMA Dec-13 |
HESTER BIOSCIENCES/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 2,852 | 3,481 | - | |
Low | Rs | 1,416 | 3,024 | - | |
Sales per share (Unadj.) | Rs | 312.7 | 1,997.6 | - | |
Earnings per share (Unadj.) | Rs | 32.9 | 124.8 | - | |
Cash flow per share (Unadj.) | Rs | 57.3 | 286.3 | - | |
Dividends per share (Unadj.) | Rs | 8.00 | 109.24 | - | |
Avg Dividend yield | % | 0.4 | 3.4 | 11.2% | |
Book value per share (Unadj.) | Rs | 328.7 | 2,219.0 | - | |
Shares outstanding (eoy) | m | 8.51 | 848.00 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 6.8 | 1.6 | 419.0% | |
Avg P/E ratio | x | 64.7 | 26.1 | 248.4% | |
P/CF ratio (eoy) | x | 37.3 | 11.4 | 327.9% | |
Price / Book Value ratio | x | 6.5 | 1.5 | 442.8% | |
Dividend payout | % | 24.3 | 87.5 | 27.7% | |
Avg Mkt Cap | Rs m | 18,152 | 2,757,874 | 0.7% | |
No. of employees | `000 | NA | 44.9 | 0.0% | |
Total wages/salary | Rs m | 560 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 37,690.2 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 2,354.5 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 2,661 | 1,693,984 | 0.2% | |
Other income | Rs m | 154 | 0 | - | |
Total revenues | Rs m | 2,814 | 1,693,984 | 0.2% | |
Gross profit | Rs m | 548 | 463,899 | 0.1% | |
Depreciation | Rs m | 207 | 136,926 | 0.2% | |
Interest | Rs m | 93 | 33,273 | 0.3% | |
Profit before tax | Rs m | 402 | 293,700 | 0.1% | |
Minority Interest | Rs m | 0 | 1,334 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -192,798 | -0.0% | |
Tax | Rs m | 121 | -3,586 | -3.4% | |
Profit after tax | Rs m | 280 | 105,822 | 0.3% | |
Gross profit margin | % | 20.6 | 27.4 | 75.2% | |
Effective tax rate | % | 30.2 | -1.2 | -2,472.1% | |
Net profit margin | % | 10.5 | 6.2 | 168.7% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 2,276 | 1,144,111 | 0.2% | |
Current liabilities | Rs m | 1,487 | 997,761 | 0.1% | |
Net working cap to sales | % | 29.7 | 8.6 | 343.2% | |
Current ratio | x | 1.5 | 1.1 | 133.5% | |
Inventory Days | Days | 47 | 91 | 52.0% | |
Debtors Days | Days | 109 | 96 | 113.9% | |
Net fixed assets | Rs m | 4,424 | 553,293 | 0.8% | |
Share capital | Rs m | 85 | 4,170 | 2.0% | |
Net worth | Rs m | 2,797 | 1,881,695 | 0.1% | |
Long term debt | Rs m | 1,849 | 866,172 | 0.2% | |
Total assets | Rs m | 6,700 | 3,871,297 | 0.2% | |
Interest coverage | x | 5.3 | 9.8 | 54.0% | |
Debt to equity ratio | x | 0.7 | 0.5 | 143.6% | |
Sales to assets ratio | x | 0.4 | 0.4 | 90.8% | |
Return on assets | % | 5.6 | 3.6 | 155.2% | |
Return on equity | % | 10.0 | 5.6 | 178.2% | |
Return on capital | % | 10.6 | 4.9 | 215.9% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 236 | 269,933 | 0.1% | |
From Investments | Rs m | -770 | -95,648 | 0.8% | |
From Financial Activity | Rs m | 418 | -323,803 | -0.1% | |
Net Cashflow | Rs m | -116 | -149,518 | 0.1% |
Compare HESTER BIOSCIENCES With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US)
Compare HESTER BIOSCIENCES With: PARENT.DRUGS LACTOSE INDIA FDC NORRIS MEDICINES SANJIVANI PA
Indian share markets continued the momentum as the session progressed and ended on firm footing.